ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1583

Low-Dose IL-2 Promotes the Proliferation of Peripheral Regulatory T Cells in Primary Sjogren’s Syndrome to Restore Its Balances with Pro-Inflammatory Lymphocytes

Miao Miao1, Zhenye Hao1, Yingying Guo1, Xiaoying Zhang1, Sheng-Xiao Zhang1, Jing Luo2, Jinfang Zhao3, Chong Gao4 and Xiao-Feng Li5, 1The Second Hospital of Shanxi Medical University, Taiyuan, China, 2the Second Hospital of Shanxi Medical University, Taiyuan, China, 3The Shanxi Medical University, Taiyuan, China, 4Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Cambridge, MA, 5Rheumatology, the Second Hospital of Shanxi Medical University, Taiyuan, China

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Sjogren's syndrome, T cells, T-Regulatory Cells and interleukins (IL)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, October 22, 2018

Title: Sjögren's Syndrome – Basic and Clinical Science Poster

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: To investigate the effect of low-dose IL-2 on the balance of Treg with Teff and other pro-inflammatory lymphocytes in peripheral blood of pSS patients.

Methods: A total of 190 pSS patients and 30 healthy controls were included in the study. The absolute numbers of total CD4+ T, CD8+ T, B, and NK cells in peripheral blood were determined using flow cytometry and BD TrucountTM tubes, while the percentage of each cell subpopulation and CD4+ cell subsets was measured, and then calculated their absolute numbers. Of the 190 patients, 88 were given subcutaneous injections of small doses of recombinant human IL-2 (rhIL-2, 50*106 IU/day for 5 days) in combination with standard therapy, including glucocorticoids, immunosuppressants, Treatment of biologics or their combinations, while other patients received only standard therapies.

Results: (1) The absolute number of peripheral Treg cells of pSS patients was significantly lower than that of normal controls. (2) The absolute number of Th17 and CD8+ T cells before treatment was not different from that of normal controls, whereas the ratios of Th17/Treg and CD8+T/Treg were higher than normal, indicating that the imbalance of them was caused by insufficient number of Treg cells. Although Th17 and CD8+ T cells increased, Treg cells increased more dramatically, so the ratio returned to normal. Similarly, Th1, Th2, NK, and B cells had similar changes, as shown in Figure 2. (3) Compared with the standard treatment group, low-dose IL-2 increased the proportion of the patients with balanced Th17/Treg, who had a more pronounced improvement in symptoms, and less usage of glucocorticoid and HCQ. (4) There were positive correlations between ESSDAI value and the ratios of Th17/Treg (r=0.121, P=0.01), Th1/Treg (ρ=0.103, P<0.05), Th2/Treg (ρ=0.123, P<0.01), B/Treg (ρ=0.122, P<0.05), CD8+T/Treg (ρ=0.107, P<0.05), but no correlation between ESSDAI value and the ratio of NK/Treg (ρ=0.011, P>0.05).

Conclusion: Low-dose rhIL-2 treatment can promote the proliferation of various cell subsets, but mainly Treg cells, indicating that this treatment can restore the overall balances of Teff/Treg, B/Treg, and NK/Treg. Thus, due to improvement of ESSDAI, the overall balances between Treg and pro-inflammation cells are more important than the change in the single cell subset.


Disclosure: M. Miao, None; Z. Hao, None; Y. Guo, None; X. Zhang, None; S. X. Zhang, None; J. Luo, None; J. Zhao, None; C. Gao, None; X. F. Li, None.

To cite this abstract in AMA style:

Miao M, Hao Z, Guo Y, Zhang X, Zhang SX, Luo J, Zhao J, Gao C, Li XF. Low-Dose IL-2 Promotes the Proliferation of Peripheral Regulatory T Cells in Primary Sjogren’s Syndrome to Restore Its Balances with Pro-Inflammatory Lymphocytes [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/low-dose-il-2-promotes-the-proliferation-of-peripheral-regulatory-t-cells-in-primary-sjogrens-syndrome-to-restore-its-balances-with-pro-inflammatory-lymphocytes/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/low-dose-il-2-promotes-the-proliferation-of-peripheral-regulatory-t-cells-in-primary-sjogrens-syndrome-to-restore-its-balances-with-pro-inflammatory-lymphocytes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology